Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus–Associated Gastric Adenocarcinoma With ERBB2 Amplification
- 1 February 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 5 (5), 370-377
- https://doi.org/10.1200/po.20.00272
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Clinical Cancer Research, 2017
- The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literatureWorld Journal of Surgical Oncology, 2017
- Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implicationsLaboratory Investigation, 2017
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical OncologyJournal of Clinical Oncology, 2017
- Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancerAnnals of Oncology, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: Disease and treatmentsWorld Journal of Gastroenterology, 2014
- Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric CarcinomaGastroenterology, 2010
- Meta-analysis Shows That Prevalence of Epstein–Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic LocationGastroenterology, 2009
- Epstein‐Barr virus associated gastric carcinoma: Epidemiological and clinicopathological featuresCancer Science, 2008